Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orthovita, a spine and orthopedic biosurgery company, has obtained certain rights to distribute an absorbable hemostat product developed by the medical device firm, Medafor.
Subscribe to our email newsletter
Under its distribution agreement with Medafor, Orthovita has the non-exclusive right to sell Vitasure in the spine and orthopedic field in the US, and certain territories outside of the US. Medafor has responsibility for manufacturing and maintaining regulatory approvals for the product.
The initial term of the agreement is scheduled to expire in December 2013 and Orthovita has the right to renew the agreement for an additional three year period if certain purchase obligations are met during the fifth year of the agreement. Orthovita expects to launch Vitasure by the third quarter of 2008 in the US and during 2009 in its territories outside of the US.
Antony Koblish, president and CEO of Orthovita, said: “We believe that, Vitasure fits exceptionally well with our sales force’s call pattern focus on spine and orthopedic surgeries and will complement the use of our Vitoss Bone Graft Substitute product line, including our newly-launched Vitoss Bioactive Foam Bone Graft Substitute product.”